Dr. Jiawen Xu received his PhD from the University of California, Davis in 2015. He has over 10 years of experience in the CDMO industry, focusing on cell line development (CLD), cell culture development, and technology development for biologics programs. His professional experience spans multiple biologics modalities, including antibodies, enzymes, vaccines, plasmids, and gene therapy vectors, bringing a broad, application-driven perspective to develop productive and stable cell lines.